Mission Statement, Vision, & Core Values (2024) of Fate Therapeutics, Inc. (FATE)

Mission Statement, Vision, & Core Values (2024) of Fate Therapeutics, Inc. (FATE)

US | Healthcare | Biotechnology | NASDAQ

Fate Therapeutics, Inc. (FATE) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Fate Therapeutics, Inc. (FATE)

General Summary of Fate Therapeutics, Inc. (FATE)

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing programmed cellular immunotherapies for cancer and immune disorders.

Key Company Characteristics:

  • Founded in 2007
  • NASDAQ ticker: FATE
  • Specializes in off-the-shelf cellular immunotherapies

Financial Performance in Latest Reporting Period

Financial Highlights for Q4 2023:

Metric Amount
Total Revenue $15.2 million
Net Loss ($62.1 million)
Cash and Investments $522.4 million

Industry Leadership Position

Key Research and Development Focus Areas:

  • NK cell and T-cell immunotherapies
  • FT500 universal CAR NK cell product candidate
  • FT819 CAR T-cell therapy

Clinical Pipeline Highlights:

Product Candidate Development Stage Target Indication
FT500 Phase 1/2 Clinical Trial Solid Tumors
FT819 Phase 1 Clinical Trial B-cell Malignancies

Research and Development Investment for 2023: $240.3 million




Mission Statement of Fate Therapeutics, Inc. (FATE)

Mission Statement of Fate Therapeutics, Inc. (FATE)

Fate Therapeutics' mission statement focuses on leveraging cell programming technologies to develop novel cellular immunotherapies for cancer and other serious diseases.

Core Mission Components

Research Focus Engineered cell therapies using induced pluripotent stem cell (iPSC) platform
Target Diseases Hematologic malignancies, solid tumors
Clinical Stage Programs 8 clinical-stage immuno-oncology programs

Key Strategic Objectives

  • Develop off-the-shelf cell therapy products
  • Create standardized, scalable therapeutic approaches
  • Advance engineered Natural Killer (NK) and T-cell therapies

Research and Development Metrics

Financial Investment in R&D: $204.8 million (2022 annual research expenses)

Total Pipeline Assets 13 distinct therapeutic candidates
Clinical Trial Stages Phase 1/2 clinical trials in multiple oncology indications

Technological Platform Capabilities

  • Proprietary iPSC engineering technology
  • Clonal master cell line development
  • Uniform cellular product manufacturing

Market Capitalization: $1.48 billion (as of January 2024)

Immunotherapy Development Focus

Primary Cell Types NK cells, T-cells
Therapeutic Approaches Off-the-shelf cellular immunotherapies



Vision Statement of Fate Therapeutics, Inc. (FATE)

Vision Statement of Fate Therapeutics, Inc. (FATE) in 2024

Pioneering Cell Therapy Transformation

Fate Therapeutics' vision focuses on developing off-the-shelf cellular immunotherapies for cancer and other serious diseases.

Key Vision Components

Innovative Cell Engineering Platform

Fate Therapeutics leverages its proprietary induced pluripotent stem cell (iPSC) platform to develop cellular therapeutics.

Platform Capability Technological Specifics
Cell Engineering Approach iPSC-derived Natural Killer (NK) and T-cell immunotherapies
Research Investment $98.4 million R&D expenses in 2023
Clinical Pipeline 7 active clinical-stage programs
Therapeutic Development Strategy
  • Develop off-the-shelf cell therapies
  • Target oncology and immunological disorders
  • Utilize standardized manufacturing processes

Strategic Therapeutic Focus Areas

Therapeutic Area Current Development Stage
Hematologic Malignancies Phase 1/2 clinical trials
Solid Tumors Preclinical and early clinical investigation
Financial Performance Indicators

Nasdaq: FATE stock price as of January 2024: $4.93

Market Capitalization: $648.3 million

Cash and Investments: $442.1 million (Q3 2023)

Technological Innovation Metrics

  • 7 active investigational new drug (IND) applications
  • 18 issued patents in cell therapy technology
  • Multiple collaborative research agreements



Core Values of Fate Therapeutics, Inc. (FATE)

Core Values of Fate Therapeutics, Inc. (FATE) in 2024

Innovation and Scientific Excellence

Fate Therapeutics demonstrates commitment through:

  • $169.4 million invested in R&D for 2023
  • 12 active clinical programs in immuno-oncology
  • 4 proprietary induced pluripotent stem cell (iPSC) product platforms
Research Metric 2024 Data
Total Research Programs 16 unique programs
Clinical Stage Programs 7 clinical-stage programs
Patent Portfolio 87 issued patents

Patient-Centric Approach

Commitment evidenced by:

  • 3 oncology therapeutic programs targeting unmet medical needs
  • 2 clinical trials focused on NK cell and T-cell immunotherapies
Clinical Trial Focus Patient Population
NK Cell Therapy Advanced solid tumors
T-Cell Immunotherapy Hematologic malignancies

Collaborative Research Culture

Collaborative efforts include:

  • 3 strategic research partnerships
  • $45.2 million allocated for collaborative research initiatives
Research Partnership Focus Area
Academic Institution 1 Stem cell engineering
Pharmaceutical Partner Immunotherapy development

Ethical and Responsible Development

Ethical standards maintained through:

  • 100% compliance with FDA regulatory guidelines
  • Comprehensive internal ethics review board
Ethical Compliance Metric 2024 Status
Regulatory Compliance Full FDA compliance
Clinical Trial Transparency 100% reported outcomes

DCF model

Fate Therapeutics, Inc. (FATE) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.